1.. Introduction
================

Atrial fibrillation (AF) is the most commonly sustained cardiac arrhythmia and is associated with substantial risk of thromboembolism and mortality \[[@r1]\]. Treatment with an oral anticoagulant (OAC) is considered standard-of-care in patients with AF at moderate to high risk of thromboembolism and is superior to dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for the prevention of ischaemic stroke and systemic embolization \[[@r2]\].

Presentation with acute coronary syndromes (ACS) and concurrent AF is common with studies reporting between 6 and 21% of patients with ACS have concurrent AF \[[@r3]\]. Patients presenting with both ACS and AF tend to be older, have more comorbidities and worse clinical outcomes \[[@r4]\]. Treatment with DAPT for one year is standard-of-care in those presenting with ACS and treatment with DAPT is superior to oral anticoagulants in those undergoing percutaneous coronary intervention (PCI) \[[@r5], [@r6]\]. Determining the optimal antithrombotic therapy in this group of patients represents an important clinical dilemma.

Current guidelines and consensus expert reports generally recommend individualizing therapy based on a patient's ischaemic and bleeding risk and frequently recommend treatment with triple therapy (TT), a combination of DAPT and OAC therapy, in those with ACS and AF \[[@r4], [@r7], [@r8]\]. However the optimal therapy for AF patients with ACS, and the risks and benefits of TT compared with DAPT in this setting have not been established. The original intent of this systematic literature review was to limit the scope of papers included to only those with pure AF and ACS populations. However, due to the limited literature this was expanded to include pure AF and either pure ACS or ACS or coronary artery disease undergoing intervention.

2.. Methods
===========

2.1.. Search Strategy
---------------------

We electronically searched Medline, Medline pending, EMBASE and Evidence-Based Medicine Reviews (EBMR) databases, using the MeSH terms "atrial fibrillation" AND "acute coronary syndromes" (all fields), "anticoagulants" OR "platelet aggregation inhibitors" (all fields), and the key words "OAC", "NOAC", "Warfarin", "Apixaban", "Rivaroxaban", "Dabigatran", "Darexaban", "triple therapy" "dual antiplatelet therapy", "Clopidogrel", "Prasugrel", Ticagrelor" and "antiplatelet" in all fields. Results were limited to English language and human populations. In addition, the reference lists of pertinent articles were manually screened for eligible articles. We limited the search strategy to results from 1st January 2000 to 31st December 2016.

2.2.. Inclusion Criteria
------------------------

Studies had to meet all of the following criteria: (1) AF patients with an ACS or coronary artery disease undergoing intervention; (2) comparison of DAPT and TT; (3) inclusion of either ischaemic and/or bleeding outcomes. Studies that were based on mixed populations on anticoagulant therapy that were not purely an AF population were excluded. Where more than one study reported on the same patient population only the most recent report was included.

2.3.. Data Extraction
---------------------

Abstracts were screened to assess eligibility. The full text article was examined for all potentially eligible studies.

3.. Results
===========

The search strategy identified 1888 titles. After the removal of duplicates 1599 abstracts were screened. A final set of 10 papers met the inclusion criteria (see Fig. **[1](#F1){ref-type="fig"}**) and details of these are given in Table **[1](#T1){ref-type="table"}**. Where author groups published more than one study from largely the same patient population (Sambola *et al*. \[[@r9], [@r10]\], Lamberts *et al*. \[[@r11], [@r12]\] & Fosbol *et al*. \[[@r13], [@r14]\]) only the most recent study was included in the current review. There was considerable heterogeneity between studies with respect to outcomes, patient numbers in the DAPT and TT arms (range n=67 to n=5486) and follow-up periods (6 months - 42 months). Of the 10 studies, only Sambola *et al*. (2016) \[[@r9]\] and Rubboli *et al*. (2014) \[[@r15]\] were prospective in nature.

The proportion of patients with an ACS ranged from 40% in Suh *et al*. (2014) \[[@r16]\] to 100% in Fosbol *et al*. (2013) \[[@r13]\]. In 6 of the 10 studies the proportion of patients with ACS was higher in the DAPT treatment arm than in the TT arm. Details of paroxysmal, persistent and permanent AF groups could not be determined and in all cases the term AF was used to collectively represent these groups. Allocation to DAPT or TT was at the discretion of the physician in 6 studies and not described in the remaining 4 studies (Table **[1](#T1){ref-type="table"}**). When treatment was physician determined there were no reports of institutional protocols or schema to assist physician decision making. Nine studies had a follow up duration greater than or equal to 12 months and in these studies there were no statements regarding the duration of either DAPT or TT, or what therapy was adopted once DAPT or TT was discontinued.

4.. Composite Ischaemic Outcomes
================================

While it was common to report on a composite endpoint, the components of this endpoint differed across the 10 studies. In 7 studies adjusted composite endpoint results were given (Table **[2](#T2){ref-type="table"}**). No individual study found a significant difference in composite end points between groups, although in 4 of the 7 studies there was a trend towards lower rates on TT (odds ratios ranged from 0.71 to 0.94) \[[@r11], [@r13], [@r17], [@r18]\].

5.. Mortality
=============

While all studies reported unadjusted mortality only three studies reported adjusted results for mortality (Table **[2](#T2){ref-type="table"}**). In Mennuni *et al*. there was 8.6% 12 month mortality in the DAPT arm compared to a 7.1% rate on TT with an adjusted odds ratio of 0.62 \[0.35-1.08\] \[[@r18]\]. In Lamberts *et al.* the 12 month mortality rates for the DAPT and TT arms were 12% and 4% respectively, with adjusted all-cause mortality reduced with TT (OR 0.61 \[0.47-0.77\]) \[[@r11]\]. Ho *et al.* reported a 6.8% mortality on DAPT compared to 6.5% on TT, with an adjusted OR 0.96 \[0.49-1.86\] \[[@r17]\]. In addition, Kang *et al*. reported propensity-score matched results and found a 3% mortality rate in the DAPT group compared to 7% in the TT group \[[@r19]\]. In the remaining studies Fosbol *et al*. reported mortality of 13.3% on DAPT *versus* 12.9% on TT without adjusted results being given \[[@r13]\], Suh *et al*. reported 11.4% mortality on DAPT, with no deaths in the 37 patients treated with TT \[[@r16]\], and Rubboli *et al*. reported 11% mortality rates in both groups \[[@r15]\]. Sambola *et al*. reported no difference in mortality with DAPT and TT arms with respect to patients with a CHA~2~DS~2~VASc of 1 (5.5% *versus* 7.4%, respectively) and those with CHA~2~DS~2~VASc of 2 or more (10.6% *versus* 9.2%, respectively) \[[@r9]\]. DeVecchis *et al*. reported 5 all-cause deaths, 1 in the DAPT group and 4 in the TT group \[[@r20]\] and Maegdefessel *et al*. reported 4 cardiovascular deaths, 3 in the DAPT group and 1 in the TT group \[[@r21]\].

6.. Stroke
==========

All 10 studies reported unadjusted stroke rates and these are given in Table **[3](#T3){ref-type="table"}**. Stroke risk information (using CHADS~2~ \[[@r22]\] or CHA~2~DS~2~VASc \[[@r23]\]) were given in 8 of these studies. In 2 of the studies the TT group had higher stroke risk than the DAPT group (Mennuni *et al.* CHADS~2~ scores 2.9 *versus* 2.5, p\<0.01 \[[@r18]\]; Ho *et al.* CHADS~2~ scores 2.6 *vs.* 2.1, p\<0.001 \[[@r17]\]), while in one the DAPT group had a higher stroke risk (Kang *et al*. CHADS~2~ scores 2.06 *vs.* 1.68, p= 0.003) \[[@r19]\]. In the studies by Suh *et al*. \[[@r16]\], Rubboli *et al*. \[[@r15]\] and Fosbol *et al*. \[[@r13]\] the TT and DAPT groups had no statistical difference in their stroke risk. Lamberts *et al*. \[[@r11]\] and Sambola *et al*. \[[@r9]\] did not report statistical comparison of stroke risks between treatment arms, but data given appear similar.

DeVecchis *et al.* did not report stroke risk for the DAPT and TT arms, but reported 1 stroke event (2%) in the 48 patients in the TT arm and no strokes in the 19 patients in the DAPT arm \[[@r20]\]. Maegdefessel *et al.* also did not report stroke risk, and reported the highest stroke rate in the DAPT arm (8.7%), and reported no stroke in the 14 patients treated with TT \[[@r21]\].

In the other 8 studies the stroke rate varied between 0.2 and 5.3%. Of the 7 studies that performed statistical analyses only Sambola *et al.* reported significantly different stroke rates based on unadjusted results, with 5.3% in the DAPT group and 1.7% in the TT group (p=0.03) \[[@r9], [@r13], [@r15]-[@r19]\].

Three studies presented adjusted results for stroke, with variable findings (see Table **[2](#T2){ref-type="table"}**). Lamberts *et al.* reported that TT significantly reduced the risk of stroke compared to DAPT (OR 0.67, 0.46-0.98) \[[@r11]\]. Both Mennuni and Ho reported results favouring DAPT (OR 4.4 \[0.45-42.3\] \[[@r18]\] and OR 1.15 \[0.21-6.35\] \[[@r17]\] respectively), however neither of these results were statistically significance. In addition Kang *et al.* presented propensity-score matched stoke results, reporting no strokes in the DAPT group and 4% in the TT group \[[@r19]\].

7.. Bleeding
============

Different definitions of bleeding were used across the 10 studies (Table **[4](#T4){ref-type="table"}**), and this resulted in differing rates of bleeding observed from a low of no bleeding to a high of 16.7% bleeding. Bleeding risk, using either HAS-BLED \[[@r24]\] or ATRIA \[[@r25]\] scores were reported in 7 of the 10 studies. In 5 of these studies there was no statistical difference in bleeding risk between treatment arms \[[@r13], [@r15], [@r16], [@r18], [@r19]\]. Lamberts *et al*. \[[@r11]\] and Sambola *et al*. \[[@r9]\] did not perform statistical analysis however bleeding risk appears to be similar in both treatment arms.

Unadjusted bleeding rates were presented in all 10 studies and significant differences were observed in 3. Kang *et al.* reported a 16.7% bleeding rate in the TT group, significantly higher than the 4.6% in the DAPT group \[[@r19]\], and Mennuni *et al*. reported an 11.5% bleeding rate for TT group compared with 6.4% for DAPT \[[@r18]\]. Sambola *et al*. \[[@r9]\] also showed higher bleeding in the TT group (8.4%) when compared to the DAPT group (3.1%). Four studies (DeVecchis *et al*. \[[@r20]\], Rubboli *et al*. \[[@r15]\], Suh *et al*. \[[@r16]\] and Ho *et al*. \[[@r17]\]) did not find significant differences between bleeding rates while three studies (Fosbol *et al*. \[[@r13]\], Lamberts *et al*. \[[@r11]\] and Maegdefessel *et al*. \[[@r21]\]) did not perform statistical analyses on unadjusted bleeding rates.

Adjusted bleeding results were presented in 6 studies (see Table **[1](#T1){ref-type="table"}**) and in 4 of these there was a statistically significant increase in bleeding associated with TT (Sambola *et al.* OR 2.97 \[1.25-7.02\], Kang *et al.* OR 6.84 \[1.98-23.6\], Lamberts *et al.* OR 2.08 \[1.64-2.65\] and Mennuni *et al.* OR 1.79, \[1.11-2.89\]). The other two studies reported non-significant increases in bleeding with TT (Fosbol *et al*. OR 1.29 \[0.96-1.74\], Ho *et al*. OR 1.25 \[0.6-2.6\]).

8.. Discussion
==============

The quality of studies identified comparing clinical outcomes for patients with AF and ACS/PCI treated with DAPT or TT was poor. Eight of the ten studies included in this review were retrospective in nature, and none of the studies adequately described the basis of treatment allocation. Only one study was of a pure ACS population, the other nine containing a mix of stable coronary artery disease patients undergoing PCI and ACS patients. There was consistency in the observation that TT was associated with an increase in the rate of bleeding. While the largest study of the ten observed a reduction in stroke and in mortality associated with TT compared to DAPT, this was not a consistent finding.

This systematic review highlights a large gap in current literature, the lack of randomised control trials assessing treatment for patients with AF and ACS. Between 6 -- 21% of patients with ACS may have concurrent AF, so this is a common clinical presentation \[[@r3]\]. In addition, a number of studies have shown that patients with AF have worse clinical outcomes following ACS than those without AF \[[@r26]-[@r28]\]. The absence of robust data on which to base treatment recommendations is therefore a significant concern. The latest ESC guidelines for NSTEMI-ACS had a number of treatment recommendations for AF and ACS patients that had level of evidence C (expert opinion) \[[@r29]\]. The studies included in this review were all observational, mostly retrospective, and some very small. A number of these studies incorporated treatment groups other than DAPT and TT although these have not been discussed here. The original intent of this review had been to limit the studies discussed to pure ACS-AF populations. However, this would have left only the study by Fosbol *et al*. included \[[@r13]\]. The change to a mixed ACS and stable coronary disease inclusion expanded the number of studies included, but at the risk of altering the characteristics of the patient population. Treatment allocation was inadequately described in all studies. While consensus documents suggest stratifying patient by risk to determine treatment regimen \[[@r4], [@r7], [@r29]\], none of the studies included in this review have stated that this was done. The similarity in stroke and bleeding risk scores between the treatment arms in the majority of studies supports this notion. There are ongoing randomised trials such as REDUAL-PCI (dual therapy with dabigatran and either clopidogrel or ticagrelor, *versus* TT with warfarin, in patients with AF undergoing PCI) \[[@r30]\] and MUSICA-2 (DAPT *vs*. TT in patients with AF and low to moderate thromboembolic risk undergoing PCI) \[[@r31]\] which when completed may provide more guidance regarding optimal pharmacological therapy, but none will directly address ACS patients with AF.

On the basis of the small number of studies in this systematic review it is evident that bleeding rates are significantly higher in patients treated with TT compared to DAPT. This was demonstrated consistently in the adjusted results, including the two largest studies, Fosbol *et al*. \[[@r13]\] and Lamberts *et al*. \[[@r11]\], with the former particularly pertinent as it was the only study to only include patients with ACS. Greater bleeding in TT groups was also supported in the majority of unadjusted results. There are some limitations that need to be noted here. Bleeding definitions used varied considerably, and the observed bleeding rates varied in part as a consequence of this. However, some of the studies that only included major bleeding reported higher rates of bleeding than others that had broader definitions of bleeding. It is possible that some bleeding was not captured in some of these studies due to the retrospective nature of most of the studies.

The bleeding results reported in this study are consistent with the data from randomised controlled trials conducted in ACS populations that have compared TT to DAPT. In ATLAS ACS 2-TIMI-51 patients were randomised to rivaroxaban low dose (2.5mg twice daily) or high dose (5mg twice daily) plus DAPT or DAPT alone \[[@r32]\]. This study reported a reduction in cardiovascular and all-cause mortality associated with the low dose of rivaroxaban (but not the higher dose) and an increase in non-CABG related major bleeding but not fatal bleeding in both TT groups. The APPRAISE-2 study examined the addition of apixaban (5mg twice daily) to DAPT. This study was halted prematurely as there was no evidence of a reduction in the composite end point of cardiovascular death, MI or ischaemic stroke associated with TT, and a significant increase in major bleeding was observed in the apixaban group \[[@r33]\]. A recent meta-analysis including the two phase III trials APPRIASE-2 and ATLAS ACS2-TIMI 51 and 5 phase II trials in ACS with DAPT and TT arms reported an increased risk of bleeding associated with TT (Hazard Ratio 2.34; 2.06-2.66) with a modest reduction in MACE (HR 0.87;0.80-0.95) \[[@r34]\]. A similar association was described in a sub-study of the RE-LY trial, demonstrating that for warfarin and both 110mg and 150mg doses of dabigatran, addition of antiplatelet agents resulted in increased major bleeding \[[@r35]\]. Furthermore, nationwide registry data from Denmark of 40,812 MI patients showed that risk of bleeding causing hospitalisation increased with the number of antithrombotic drugs used, with those on TT at highest risk (compared to aspirin, DAPT HR 1.47 (1.28-1.69), TT HR 4.05 (3.08-5.33) \[[@r36]\]. Taking the results from these studies together with the findings in this review, it seems highly likely that TT in AF and ACS patients will result in an increase in clinically important bleeding.

The efficacy of TT was less clear in the studies reviewed here. It might have been expected that the major benefit of TT would be seen in a reduction in the rate of stroke. This is based on meta-analysis of AF studies, showing superiority of warfarin to antiplatelet therapy for the reduction in stroke \[[@r37]\]. Consistent with this, the largest study included in this review did observe a reduction in stroke associated with TT \[[@r11]\]. However the second largest study, Fosbol *et al.* reported a 2.2% rate of stroke on DAPT and a 1.6% rate on TT, which were not significantly different in unadjusted analysis. Three other studies reported a trend towards higher stroke rates on TT in adjusted analysis, although in none of these cases was a statistically significant result observed \[[@r17]-[@r19]\]. These results suggest that the benefits of adding warfarin to DAPT for stroke prevention in the context of ACS in AF patients is not clear.

It is also unclear that there is a reduction in composite ischaemic endpoints or in mortality associated with TT, although in the case of mortality Lamberts *et al*. did demonstrate a mortality advantage \[[@r11]\]. Whilst it is conceivable that addition of and OAC to DAPT may reduce mortality related to thromboembolic events \[[@r32]\], it is also clear that major bleeding events in patients with ACS are associated with an increase in mortality \[[@r38], [@r39]\].

The ESC AF guidelines of 2014 \[[@r8]\] include a structured algorithm based on stroke risk and bleeding risk to determine the combination of antithrombotic and antiplatelet therapy. The subsequent ESC NSTEM-ACS guidelines of 2015 \[[@r29]\] present a simplified version that does recommend TT for all ACS patients undergoing PCI, for 1 month in those with high bleeding risks and 6 months for those with lower bleeding risk, followed by dual therapy (clopidogrel and anticoagulation) out to 12 months. Bleeding risk in this context is defined by HASBLED\[[@r24]\], and while this score has been well validated in AF, it has not been validated in AF and ACS. The current ACC/AHA STEMI \[[@r40]\] and NSTEMI \[[@r41]\] guidelines both note the increased risk of bleeding associated with TT, and suggest that where this is warranted, an INR of 2.0 to 2.5 might be considered. The ACC/AHA guidelines do not reference a bleeding score. The studies included in the current review showed similar bleeding scores in both treatment arms suggesting that bleeding risk was not strongly associated with treatment allocation. In three studies there was a higher stroke risk in the TT arm, which may indicate stroke risk was a factor in treatment allocation in at least some cases.

Within the ESC guidelines \[[@r8], [@r29]\] the term OAC is used and refers to either well-controlled warfarin or one of the novel oral anticoagulants. It is important to note that all of the studies in this review that used oral anticoagulants were using a vitamin K antagonist (VKA), predominantly warfarin, and it is entirely possible that the use of novel oral anticoagulants would result in a different safety-efficacy ratio Whilst there is lack of supporting evidence in this context, the superiority of the novel oral anticoagulants over warfarin for stroke prevention in AF patients has been demonstrated \[[@r42]-[@r45]\] and therefore the ESC suggestion of anticoagulation using these agents may be logical. Current ACC/AHA guidelines limit comment to warfarin on the basis that data is lacking for the newer agents \[[@r40]\]. With regard to DAPT therapy all of the studies in this review are referring to an aspirin and clopidogrel combination. The ESC guidelines advocate the use of aspirin and clopidogrel to constitute DAPT in the context of AF, but not the newer P2Y~12~ receptor inhibitors prasugrel and ticagrelor, based on no proven benefit in the AF and ACS population. Both prasugrel and ticagrelor have both been shown to be superior to clopidogrel on the basis of the TRITON-TIMI 38 \[[@r46]\] and PLATO \[[@r47]\] trials respectively. However, these agents were both associated with increased risks of non-CABG related bleeding compared to clopidogrel. The absence of even observational data describing outcomes in AF and ACS patients treated with the newer anticoagulants and antiplatelet agents is striking and further demonstrates the paucity of data to guide clinical decision making in treating this group of patients.

This review has focused exclusively on the comparison of DAPT and TT. However, the combination of OAC and a single antiplatelet agent for AF and ACS patients may be important to consider. Lamberts *et al.* included both aspirin and warfarin, and aspirin and clopidogrel treatment arms in their study, and found both resulted in significantly less bleeding than TT, without any difference in rates of stroke \[[@r11]\]. The WOEST trial, examined OAC + antiplatelet (VKA + clopidogrel) to TT (VKA + clopidogrel + aspirin) in a slightly different population (69% AF and only 25-30% ACS). At 1 year follow-up significantly less total bleeding occurred in the oral anticoagulant plus clopidogrel group (HR 0.36, \[0·26-0·50\], p\<0.0001), with no difference in major bleeding detectable. This reduction in bleeding was accompanied with a decreased rate of thrombotic events (composite of MI, stroke, TVR and stent thrombosis) (HR 0.6, \[0.38-0.94\], p=0.025), and showed an all-cause mortality benefit over TT (HR 0.39, \[0.16-0.93\], p=0.027) \[[@r48]\]. The recently completed PIONEER AF-PCI study examined dual therapy (rivaroxaban and P2Y~12~ inhibitor), *versus* TT with rivaroxaban or warfarin, in AF patients undergoing PCI, with about 50% of the patients having ACS. There was no DAPT arm in this study, so the study did not meet the inclusion criteria for our systematic review. The warfarin, aspirin, P2Y12 inhibitor arm of this study had the highest bleeding rate, and the lowest bleeding rate was observed in the rivaroxaban-clopidogrel arm. The study was not powered to examine efficacy, and no difference in MACE between groups was reported \[[@r49]\]. While it is possible that some combination of novel OAC and a single antiplatelet agent may be superior to DAPT or TT, this is not currently recommended therapy within guidelines. Examining the utility of an oral anticoagulant and a single antiplatelet agent may therefore have merit. This area is now considerably more complex, as the novel oral anticoagulants and new antiplatelet drugs provide an increased range of possible therapeutic combinations, at a range of dosing options, that adds to the confusion in how best to treat AF patients with ACS.

9.. Study Limitations
=====================

We excluded a number of studies that were based on populations on oral anticoagulant treatment at the time of an ACS event. These studies would have included mostly AF patients, mixed with a smaller proportion of patients with mechanical valves, DVT/PE or other indications for anticoagulation. Our rationale for this exclusion was that the non-AF patients included have quite a different risk profile, and that many patients with AF and ACS may not have been on an anticoagulant at the time of the ACS. We did choose to include studies that were not in pure ACS patients, as had we not done so, only one study would have been included in the review. Meta-analyses were not performed due to heterogeneity of eligible studies and absence of randomised control trials. Information regarding the duration of either DAPT or TT, or what default therapy was once DAPT or TT was discontinued was inadequately described in all studies; therefore we were unable to draw inferences about optimal duration of therapy on the basis of our results.

Conclusion
==========

Optimal drug therapy in patients with AF and ACS is complex as both atherothrombotic and thromboembolic protection is required. The existing literature comparing DAPT to TT for this group of patients was poor in quality, consisting predominantly of retrospective studies with mixed ACS and PCI patients. There was a lack of detail on treatment allocation, and important differences in the clinical characteristics of DAPT and TT treatment arms were often not accounted for. Where adjusted results were presented, TT was consistently associated with an increase in bleeding risk, but there was not consistent evidence of reduced stroke, or reduced composite ischaemic endpoints associated with TT. This review has highlighted the need for prospective randomised control trials to define optimal therapy and improve outcomes in the AF and ACS population.
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###### 

Overview of included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                                 **Follow-up**        **Population**         **Design**      **Data Source**                           **Groups**       **Allocation**
  ----------------------------------------- -------------------- ---------------------- --------------- ----------------------------------------- ---------------- ---------------------
  Sambola *et al*.\                         12 months            AF + PCI               Prospective     Hospital database                         DAPT (n=266)\    Physician allocated
  (2016) \[[@r9]\]                                                                                                                                TT (n=319)       

  De Vecchis *et al*.\                      378 ± 15.9 days      AF + PCI               Retrospective   Hospital database                         DAPT (n=19)\     Physician allocated
  (2016) \[[@r20]\]                                                                                                                               TT (n=48)        

  Kang *et al*.\                            20.6 ± 7.4 months    AF + DES               Retrospective   Hospital database                         DAPT (n=236)\    Physician allocated
  (2015) \[[@r19]\]                                                                                                                               TT (n=131)       

  Mennuni *et al*.\                         12 months            AF + PCI               Retrospective   Hospital databases                        DAPT (n=488)\    Physician allocated
  (2015) \[[@r18]\]                                                                                                                               TT (n=371)       

  Rubboli *et al*.\                         12 months            AF + PCI               Prospective     Hospital databases                        DAPT (n=162)\    Physician allocated
  (2014) \[[@r15]\]                                                                                                                               TT (n=679)       

  Suh *et al*.\                             42.0 ± 29.0\         AF + PCI               Retrospective   Medical centre database                   DAPT (n=166)\    Physician allocated
  (2014) \[[@r16]\]                         months                                                                                                TT (n=37)        

  Fosbol *et al*.\                          12 months            AF + NSTEMI with PCI   Retrospective   CRUSADE registry and insurance database   DAPT (n=1200)\   Not stated
  (2013) \[[@r13]\]                                                                                                                               TT (n=448)       

  Lamberts *et al*.\                        12 months            AF + MI and/or PCI     Retrospective   Not stated                                DAPT (n=3590)\   Not stated
  (2013) \[[@r11]\]                                                                                                                               TT (n=1896)      

  Ho *et al*.\                              5.9 ± 5.0 months     AF + PCI               Retrospective   Not stated                                DAPT (n=220)\    Not stated
  (2013) \[[@r17]\]                                                                                                                               TT (n=382)       

  Maegdefessel *et al*. (2008) \[[@r21]\]   16.8 (2-68) months   AF + PCI               Retrospective   Hospital database                         DAPT (n=103)\    Not stated
                                                                                                                                                  TT (n=14)        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Length of follow up is in months ± standard deviation or months (range); AF = atrial fibrillation; DAPT = dual antiplatelet therapy; DES = drug eluding stent; MI = myocardial infarction; NSTEMI = non ST elevation myocardial infarction; PCI = percutaneous coronary intervention; TT = triple therapy.

###### 

Adjusted outcomes.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                             **DAPT Patients**   **TT**\        **Composite Endpoint**                                       **OR**\              **OR**\                **OR**\                **OR**\
                                                            **Patients**                                                                **Composite**        **Mortality**          **Stroke**             **Bleeding**
  ------------------------------------- ------------------- -------------- ------------------------------------------------------------ -------------------- ---------------------- ---------------------- ------------------------
  Sambola *et al*. (2016) \[[@r9]\]     N=266\              N=319\         Mortality, MI, stent thrombosis, repeat revascularisation    1.05 (0.67-1.86)     \-                     \-                     2.97 (1.25-7.02)\*\*
                                        79% ACS             68% ACS                                                                                                                                        

  Kang *et al*. (2015) \[[@r19]\]       N= 99\              N= 99\         Mortality, MI, repeat revascularisation, stroke              1.57 (0.82-2.99) †   3% DAPT *vs.* 7% TT†   0% DAPT *vs.* 4% TT†   6.84 (1.98-23.6)\*\* †
                                        73.7% ACS           76.7% ACS                                                                                                                                      

  Mennuni *et al*. (2015) \[[@r18]\]    N=488,\             N=371,\        Mortality, MI, stroke                                        0.77 (0.52-1.14)     0.62 (0.35-1.08)       4.4 (0.45-42.3)        1.79 (1.11-2.89)\*
                                        57% ACS             54% ACS                                                                                                                                        

  Rubboli *et al*. (2014) \[[@r15]\]    N=162,\             N=679,\        Mortality, MI, stent thrombosis, revascularisation, stroke   1.17 (0.57-2.5)      \-                     \-                     \-
                                        66% ACS             54% ACS                                                                                                                                        

  Fosbol *et al*. (2013) \[[@r13]\]     N=1200,\            N=448,\        Mortality, MI, stroke                                        0.94 (0.73-1.21)     \-                     \-                     1.29 (0.96-1.74)
                                        100% ACS            100% ACS                                                                                                                                       

  Lamberts *et al*. (2013) \[[@r11]\]   N=3590,\            N=1896,\       MI, Coronary death                                           0.83 (0.68-1.0)      0.61 (0.47-0.77)\*     0.67 (0.46-0.98)\*     2.08 (1.64-2.65)\*
                                        72% ACS             53% ACS                                                                                                                                        

  Ho *et al*.\                          N=220,\             N=382,\        Mortality, ischemic stroke, TIA                              0.71 (0.37-1.38)     0.96 (0.49-1.86)       1.15 (0.21-6.35)       1.25 (0.6-2.6) ‡
  (2013) \[[@r17]\]                     68% ACS             71% ACS                                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Odds ratios (OR) are given relative to dual antiplatelet therapy (DAPT). Abbreviations ACS = acute coronary syndrome; MI = myocardial infarction; TIA = transient ischemic attack; TT = triple therapy. Statistically significant results are given by \* p \< 0.05, \*\* p \< 0.01 \*\*\* p \<0.001.†=results were propensity-score matched, not adjusted; ‡ Bleeding odds ratio was for the subgroup of patients with a CHADS~2~ score of greater than 2.

###### 

Unadjusted stroke rates.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                                 **DAPT Patients**   **DAPT Stroke Risk**        **DAPT Stroke Rate (%)**   **TT**\        **TT Stroke Risk**          **TT Stroke Rate (%)**
                                                                                                                       **Patients**                               
  ----------------------------------------- ------------------- --------------------------- -------------------------- -------------- --------------------------- ------------------------
  Sambola *et al*.\                         N=266\              45% CHA~2~DS~2~VASc 2+      5.3\*                      N=319\         56% CHA~2~DS~2~VASc 2+      1.7
  (2016) \[[@r9]\]                          79% ACS                                                                    68% ACS                                    

  DeVecchis *et al*.\                       N=19\               Not given                   0                          N=48\          Not given                   2
  (2016) \[[@r20]\]                         68% ACS                                                                    69% ACS                                    

  Kang *et al*.\                            N=236,\             Mean CHADS~2~: 1.68\*       2.1                        N=131,\        Mean CHADS~2~: 2.06         3
  (2015) \[[@r19]\]                         77.4% ACS                                                                  77.8% ACS                                  

  Mennuni *et al*.\                         N=488,\             Mean CHADS~2~: 2.5\*        0.2                        N=371,\        Mean CHADS~2~: 2.9          1.2
  (2015) \[[@r18]\]                         57% ACS                                                                    54% ACS                                    

  Rubboli *et al*.\                         N=162,\             Mean CHADS~2~: 2.1          4                          N=679,\        Mean CHADS~2~: 2.3          2
  (2014) \[[@r15]\]                         66% ACS                                                                    54% ACS                                    

  Suh *et al*.\                             N=166,\             65% CHADS~2~ 2+\            3.6                        N=37,\         57% CHADS~2~ 2+\            2.7
  (2014) \[[@r16]\]                         43% ACS             Mean score: 1.95                                       33% ACS        Mean score: 1.81            

  Fosbol *et al*.\                          N=1200, 100% ACS    Median CHA~2~DS~2~VASc: 4   2.2                        N =448,\       Median CHA~2~DS~2~VASc: 4   1.6
  (2013) \[[@r13]\]                                                                                                    100% ACS                                   

  Lamberts *et al*.\                        N=3590,\            90% CHA~2~DS~2~VASc 2+      4.2†                       N=1896,\       90% CHA~2~DS~2~VASc 2+      1.8
  (2013) \[[@r11]\]                         72% ACS                                                                    53% ACS                                    

  Ho *et al*.\                              N=220,\             Mean CHADS~2~: 2.1\*        0.9                        N=382,\        Mean CHADS~2~: 2.6          1.1
  (2013) \[[@r17]\]                         68% ACS                                                                    71% ACS                                    

  Maegdefessel *et al*. (2008) \[[@r21]\]   N=103,\             Not given                   8.7†                       N=14,\         Not given                   0
                                            88% ACS                                                                    72% ACS                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACS = acute coronary syndrome; DAPT= dual antiplatelet therapy; TT = triple therapy. Statistically significant differences between treatment arms are indicated by \* p \<0.05.† statistical comparison of stroke rates not performed.

###### 

Unadjusted bleeding rates.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                                 **DAPT Patients**   **DAPT Bleeding Risk**   **DAPT Bleeding Rate (%)**   **TT Patients**   **TT Bleeding Risk**     **TT Bleeding Rate (%)**   **Bleeding Definition**
  ----------------------------------------- ------------------- ------------------------ ---------------------------- ----------------- ------------------------ -------------------------- -------------------------------------------------------------------
  Sambola *et al*.\                         N=266\              HASBLED ≥3, 37%          3.1\*                        N=319\            HASBLED ≥3, 42%          8.4                        TIMI Major
  (2016) \[[@r9]\]                          79% ACS                                                                   68% ACS                                                               

  DeVecchis *et al*. (2016) \[[@r20]\]      N=19\               Not given                5.3                          N=48\             Not given                8.3                        Major bleeding -- not defined
                                            68% ACS                                                                   69% ACS                                                               

  Kang *et al*.\                            N=236, 77.4% ACS    HASBLED, mean 2.1        4.6\*                        N=131,\           HASBLED, mean 2.2        16.7                       Intracerebral or hemodynamic compromise
  (2015) \[[@r19]\]                                                                                                   77.8% ACS                                                             

  Mennuni *et al*.\                         N=488,\             HASBLED, mean 2.9        6.4\*                        N=371,\           HASBLED, mean 2.9        11.5                       BARC 2+
  (2015) \[[@r18]\]                         57% ACS                                                                   54% ACS                                                               

  Rubboli *et al*.\                         N=162,\             HASBLED, mean 2.9        12                           N=679,\           HASBLED, mean 2.9        10                         BARC3 & 5
  (2014) \[[@r15]\]                         66% ACS                                                                   54% ACS                                                               

  Suh *et al*.\                             N=166,\             HASBLED, mean 2.0        0.6                          N=37,\            HASBLED, mean 1.9        2.7                        Overt bleeding, need for transfusion, intracranial bleeding
  (2014) \[[@r16]\]                         42% ACS                                                                   33%ACS                                                                

  Fosbol *et al*. (2013) \[[@r13]\]         N=1200, 100% ACS    ATRIA, median 3          11.9†                        N =448,\          ATRIA, median 3          14.4                       Bleeding causing hospital admission
                                                                                                                      100% ACS                                                              

  Lamberts *et al*. (2013) \[[@r11]\]       N=3590,\            HASBLED ≥3, 24.3%        4.6†                         N=1896,\          HASBLED ≥3, 24.3%        6.2                        Bleeding causing hospital admission or death
                                            72% ACS                                                                   53% ACS                                                               

  Ho *et al*. (2013) \[[@r17]\]             N=220,\             No bleeding risk score   9.6                          N=382,\           No bleeding risk score   10.6                       Bleeding requiring transfusion
                                            68% ACS                                                                   71% ACS                                                               

  Maegdefessel *et al*. (2008) \[[@r21]\]   N=103,\             No bleeding risk score   1.9†                         N=14,\            No bleeding risk score   0                          Not defined in methods -- requiring transfusion stated in results
                                            89% ACS                                                                   72% ACS                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACS = acute coronary syndrome; BARC = Bleeding academic research consortium \[[@r48]\]; DAPT = dual antiplatelet therapy; TT = triple therapy. Statistically significant differences between treatment arms are indicated by \* p \<0.05.† statistical comparison of stroke rates not performed.
